Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tim Eisen

Showing results (51-60 of 116) with videos related to

Pageof 12
Sort By:
Trends in Neurosciences|November 23, 2016
The CHRNA5-A3-B4 Gene Cluster and Smoking: From Discovery to TherapeuticsGlenda Lassi, Amy E Taylor, Nicholas J Timpson, et al.
European Journal of Cancer (Oxford, England : 1990)|March 17, 2018
Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 studyAna M Molina, Thomas E Hutson, Dmitry Nosov, et al.
Melanoma Research|May 14, 2009
Phase II study of biweekly plitidepsin as second-line therapy in patients with advanced malignant melanomaTim Eisen, José Thomas, Wilson H Miller, et al.
Scandinavian Journal of Urology|January 28, 2015
Diagnostic accuracy of preoperative computed tomography used alone to detect lymph-node involvement at radical nephrectomyStephen S Connolly, Aditya Raja, Helen Stunell, et al.
The Journal of Urology|October 23, 2012
Improvement in overall survival of patients with advanced renal cell carcinoma: prognostic factor trend analysis from an international data set of clinical trialsSujata Patil, Judith Manola, Paul Elson, et al.
European Journal of Cancer (Oxford, England : 1990)|July 27, 2010
Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGETThomas E Hutson, Joaquim Bellmunt, Camillo Porta, et al.
Lung Cancer (Amsterdam, Netherlands)|August 12, 2008
Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancerTim Eisen, Nick Thatcher, Serge Leyvraz, et al.
Lung Cancer (Amsterdam, Netherlands)|September 14, 2007
Ensuring the right PET scan for the right patientStephen G Spiro, John Buscombe, Gary Cook, et al.
Genome Research|June 3, 2006
Variants in the GH-IGF axis confer susceptibility to lung cancerMatthew F Rudd, Emily L Webb, Athena Matakidou, et al.
Journal of the National Cancer Institute|October 9, 2008
Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trialTim Eisen, Stéphane Oudard, Cezary Szczylik, et al.
Pageof 12

Showing results (51-60 of 116) with videos related to

Sort By:
Pageof 12
Trends in Neurosciences|November 23, 2016
The CHRNA5-A3-B4 Gene Cluster and Smoking: From Discovery to TherapeuticsGlenda Lassi, Amy E Taylor, Nicholas J Timpson, et al.
European Journal of Cancer (Oxford, England : 1990)|March 17, 2018
Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 studyAna M Molina, Thomas E Hutson, Dmitry Nosov, et al.
Melanoma Research|May 14, 2009
Phase II study of biweekly plitidepsin as second-line therapy in patients with advanced malignant melanomaTim Eisen, José Thomas, Wilson H Miller, et al.
Scandinavian Journal of Urology|January 28, 2015
Diagnostic accuracy of preoperative computed tomography used alone to detect lymph-node involvement at radical nephrectomyStephen S Connolly, Aditya Raja, Helen Stunell, et al.
The Journal of Urology|October 23, 2012
Improvement in overall survival of patients with advanced renal cell carcinoma: prognostic factor trend analysis from an international data set of clinical trialsSujata Patil, Judith Manola, Paul Elson, et al.
European Journal of Cancer (Oxford, England : 1990)|July 27, 2010
Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGETThomas E Hutson, Joaquim Bellmunt, Camillo Porta, et al.
Lung Cancer (Amsterdam, Netherlands)|August 12, 2008
Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancerTim Eisen, Nick Thatcher, Serge Leyvraz, et al.
Lung Cancer (Amsterdam, Netherlands)|September 14, 2007
Ensuring the right PET scan for the right patientStephen G Spiro, John Buscombe, Gary Cook, et al.
Genome Research|June 3, 2006
Variants in the GH-IGF axis confer susceptibility to lung cancerMatthew F Rudd, Emily L Webb, Athena Matakidou, et al.
Journal of the National Cancer Institute|October 9, 2008
Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trialTim Eisen, Stéphane Oudard, Cezary Szczylik, et al.
Pageof 12